Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214032 · ClinicalTrials.gov registry record · Phase 2
Pycnogenol for the Treatment of Lymphedema
A Phase 2 study of Lymphedema, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT00214032: Completed Phase 2 study of Lymphedema, sponsored by University of Wisconsin, Madison.
NCT00214032 is a Phase 2 study of Lymphedema that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 2 participants, below the 9,300-participant average among 34 other Lymphedema trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00214032, a Phase 2 study of Lymphedema, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to evaluate the effectiveness of Pycnogenol (French maritime pine bark extract) for arm lymphedema in women following treatment for breast cancer, to evaluate the accuracy and sensitivity of bioelectric impedence as a measurement of lymphedema of the arm, and to validate the proposed arm lymphedema quality-of-life questionnaire.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pycnogenol
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2002-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00214032 record still lists
NCT00214032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 9,300-participant average among 34 other Lymphedema trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Lymphedema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00214032 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00214032 about?
NCT00214032 is a clinical study titled "Pycnogenol for the Treatment of Lymphedema". The objectives of this study are to evaluate the effectiveness of Pycnogenol (French maritime pine bark extract) for arm lymphedema in women following treatment for breast cancer, to evaluate the accuracy and sensitivity of bioelectric impedence as a measurement of lymphedema of the arm, and to vali...
What is the current status of trial NCT00214032?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2002-05. Estimated completion is 2007-01.
What conditions does trial NCT00214032 study?
This clinical trial studies the following conditions: Lymphedema.
What interventions are being tested in trial NCT00214032?
The interventions under investigation include: Placebo (DRUG), Pycnogenol (DRUG).
Who is sponsoring clinical trial NCT00214032?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00214032 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00214032's enrollment target sits among peer trials
2 35th of 34 the lowest of 34 other Lymphedema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphedema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
RECRUITING · Phase 2
-
Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.
RECRUITING · Phase 2
-
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
RECRUITING · Phase 2
-
Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)
COMPLETED · Phase 2
-
A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
COMPLETED · Phase 2
-
Lymphedema Surveillance Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia